Sirtris, Helicos file IPOs
Sirtris Pharmaceuticals has filed a $60 million IPO with the SEC. Sirtris is testing a "resveratrol-based" drug against diabetes. Resveratrol recently gained attention when several studies suggested that the compound, which is found in red wine, can be used to counter the ailments associated with age and obesity. The number of shares to be offered and the price range for the offering have not yet been determined.
- check out Sirtris' press release
PLUS: Helicos BioSciences has filed a $100 million IPO. Helicos is developing genetic analysis technologies for the research, drug discovery and clinical diagnostics markets. Release
ALSO: Canada's OncoGenex has cut its planned initial public offering to $7.50 to $8.50 per share from a previous range of $10 to $12. Release
Related Articles:
Ingredient in wine may boost longevity, health. Report
Sirtris pockets $37M in venture funds. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
